ArticlePloS one2026

Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis.

Yu Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.